Entelo Bio, a venture backed biotechnology company pioneering the emerging isoform frontier of medicine, releases Flow Agent, an adaptive agentic (autonomous, AI-driven) based workflow management framework for bioinformatics workflows.
Stay updated with the latest BioEscalator updates, tenant and alumni news, and upcoming events in the Spring 2025 edition of the BioEscalator Bulletin.
OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that Birgitte Volck MD, PhD has joined its Board as a non-executive director.
Andreas Halner, president and co-founder of Oxford Cancer Analytics (OXcan), chats to TheHill director, Megan Morys-Carter, about the company's inception, what makes the technology so revolutionary and the ever-increasing success OXcan has met with recently.
Collaboration may inform future combination strategies that can maximise the efficacy of Enara Bio\u2019s pipeline of TCR-based immunotherapies targeting Dark Antigens\u00ae
Scientists in Cambridge have developed a new \u2018super test\u2019 for prostate cancer in an effort to revolutionise screening and diagnosis of the disease and accelerate personalised treatment for patients.
The BioEscalator is delighted to have launched its inaugural Annual Review, \u2018Driving innovation, advancing human health \u2019. It provides for the first time a discussion of our achievements in 2023/24, plus the milestones from our initial five years of operation.
The guide showcases Britain's fastest-growing private tech companies from The Sunday Times, commercialising innovation across the UK.\r\n\r\n\"This recognition is a testament to our innovative science and the hard work of our incredible team as we strive to develop safe and effective treatments for cancer patients.\" Enara Bio
U-Ploid, a venture-backed biotechnology company developing next-generation fertility therapeutics, is pleased to announce the appointment of Professor Alison Campbell to its Advisory Board. In this key role, Professor Campbell will provide strategic guidance on company research programmes, working closely with the U-Ploid team to drive innovation in fertility treatments.
The agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform.
David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology joins Theolytics. Dr Apelian joins as the company advances its first clinical trial with lead candidate THEO-260 in ovarian cancer.
Spin-out company Alethiomics, focused on the development of innovative treatments for blood cancers, is Oxford through-and-through. Founded by Clinician Scientists who run neighbouring laboratories at the University\u2019s MRC Weatherall Institute of Molecular Medicine, seed financed by Oxford Science Enterprises and located at the BioEscalator, the company\u2019s early years have been immersed in the Oxford innovation ecosystem.
OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that the Company has promoted Dr Hsin Loke to Chief Operating Officer (COO) and Jon Roffey Ph.D. to Senior Vice President, Discovery and Non-Clinical, effective immediately.
TechBio startup, Exogene, is leveraging artificial intelligence (AI) to develop innovative immunotherapies with the potential to eliminate untreatable solid tumours in cancer patients. Through a collaboration with German company Alithea Bio, Exogene hopes to speed up cancer immunotherapy discovery and make it more cost-effective.
Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has dosed the first patient in its Phase I/IIa multi-centre, open-label first-in-human trial (OCTOPOD - NCT06618235) of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer (PROC).
OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Professor Steven Charlton as Chief Scientific Officer (CSO), effective 1 December 2024. He will take on the role from Dr Ali Jazayeri, who is leaving OMass to pursue other opportunities.
Through UK-Germany Collaborative R&D funding, Exogene is collaborating with the German company Alithea Bio, aiming to accelerate cancer immunotherapy discovery and make it more cost-effective.
CyanoCapture is making significant strides in advancing sustainable carbon capture technologies with its involvement in two major projects. Both initiatives highlight CyanoCapture's commitment to pioneering carbon-negative solutions and driving progress toward a sustainable, low-carbon future.
![\"Entelo](\"https://www.bioescalator.ox.ac.uk/news-and-events/news/entelo-bio-ushering-in-new-ways-of-doing-science/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n